In accordance with some embodiments, systems, methods, and media for automatically segmenting and diagnosing prostate lesions using multi-parametric magnetic resonance imaging (mp-MRI) data are provided. In some embodiments, the system comprises is programmed to: receive mp-MRI data depicting a prostate, including T2w data and ADC data; provide the T2w data and ADC data as input to first and second input channels of a trained convolutional neural network (CNN); receive, from the trained CNN, output values from output channels indicating which pixels are likely to correspond to a particular class of prostate lesion, the channels corresponding to predicted aggressiveness in order of increasing aggressiveness, identify a prostate lesion in the data based on output values greater than a threshold; predict an aggressiveness based on which channel had values over the threshold; and present an indication that a prostate lesion of the predicted aggressiveness is likely present in the prostate.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G06K 9/62 - Methods or arrangements for recognition using electronic means
G06N 3/02 - Computer systems based on biological models using neural network models
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
Embodiments of the disclosure include compositions and methods related to engineered invariant natural killer T (iNKT) cells for off-the-shelf use for clinical therapy. In particular embodiments, the iNKT cells are produced from hematopoietic stem progenitorcells and also are suitable for allogeneic cellular therapy because they are HLA negative. In specific embodiments, the cells are cultured in a particular in vitro three-dimensional artificial thymic organoid system and the cells have imaging and suicide targeting capabilities.
Small molecules compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
Methods for treating age-related eye diseases or conditions are provided. Methods for treating an age-related eye disease or condition in a subject by administering one or more demethylation compounds or agents are provided.
C12P 7/64 - Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
5.
SINGLE-CHAIN BISPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER
Methods and compositions are provided concerning a bispecific chimeric antigen receptor (CAR) targeting BCMA and CS1, particularly in multiple myeloma patients. The bispecific CAR has advantages over dual or separate BCMA and CS1 CAR molecules. In some embodiments, there is a bispecific chimeric antigen receptor comprising a) a bispecific extracellular binding domain comprising both i) a BCMA-binding region and ii) a CS1- binding region; b) a single transmembrane domain; and, c) a single cytoplasmic region comprising a primary intracellular signaling domain.
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Provided herein are stem-cell based therapies for the treatment of neurodegenerative diseases and CNS disorder such as Huntington's disease. The therapy improved motor deficits and rescued synaptic alterations. The cells were shown to be electrophysiologically active and that they improved motor and late-stage cognitive impairment.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Infusion sets for subcutaneous drug delivery are described herein. The infusion set integrates a bijel-templated material (BTM) into a cannula such that a portion of the BTM protrudes from the cannula tip into the host tissue. The BTM is a porous, polymeric sponge having a co-continuous architecture with consistent curvature throughout non-constricting, interpenetrating channels, which is critical in mitigation of the deleterious host tissue response, vascularization, and flow redistribution in the implant.
A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
A61L 31/14 - Materials characterised by their function or physical properties
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
8.
MULTISTRAIN POPULATION CONTROL SYSTEMS AND METHODS
Provided herein are multi-strain population control systems, methods, kits, and compositions. Also provided are methods, systems, kits, and compositions for culturing bacterial cells in multi-strain ecosystems, and temporally arranged multi-strain ecosystems or cultures using a synchronized lysis circuit in combination with multiple toxin/antitoxin systems to cycle continuously over a long period of time.
Provided are methods of producing nucleic acid libraries. The methods include combining single-stranded nucleic acid binding protein-bound single-stranded nucleic acid (SSB-bound ssNA), an adapter oligonucleotide, and a splint oligonucleotide, to form complexes including the splint oligonucleotide hybridized to a terminal region of the SSB-bound ssNA and to the adapter oligonucleotide. An end of the first adapter oligonucleotide is adjacent to an end of the first terminal region of the SSB-bound ssNA, and the methods may further include covalently linking the adjacent ends. Also provided are compositions and kits that find use, e.g., in practicing the methods of the present disclosure.
An imaging flow cytometer device includes a housing holding a multi-color illumination source configured for pulsed or continuous wave operation. A microfluidic channel is disposed in the housing and is fluidically coupled to a source of fluid containing objects that flow through the microfluidic channel. A color image sensor is disposed adjacent to the microfluidic channel and receives light from the illumination source that passes through the microfluidic channel. The image sensor captures image frames containing raw hologram images of the moving objects passing through the microfluidic channel. The image frames are subject to image processing to reconstruct phase and/or intensity images of the moving objects for each color. The reconstructed phase and/or intensity images are then input to a trained deep neural network that outputs a phase recovered image of the moving objects. The trained deep neural network may also be trained to classify object types.
A microfluidic tissue dissociation and filtration device simultaneously filters large tissue fragments and dissociates smaller aggregates into single cells, thereby improving single cell yield and purity. The device includes an inlet coupled to a first microfluidic channel at an upstream location and a first outlet at a downstream location. A first filter membrane is interposed between the first microfluidic channel and a second microfluidic channel, wherein the second microfluidic channel is in fluidic communication with the first microfluidic channel via the first filter membrane. The first filter membrane operates under a tangential flow format. A second outlet is coupled to a downstream location of the second microfluidic channel and includes a second filter membrane interposed between the second outlet and the second microfluidic channel. The dual membrane device increased single cell numbers by at least 3-fold for different tissue types.
A reaction process comprises feeding a feed stream comprising a hydrocarbon into a vessel, reacting the feed stream in the vessel, producing solid carbon and a gas phase product based on the contacting of the feed stream with the molten salt mixture, separating the gas phase product from the molten salt mixture, and separating the solid carbon from the molten salt mixture to produce a solid carbon product. The vessel comprises a molten salt mixture, and the molten salt mixture comprises a reactive component.
B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
Methods of tagging cells with unique oligonucleotide "zipcode" constructs are provided. By these methods and associated compositions, cells in a multicellular structure such as a tissue section can be tagged with a construct, the unique composition of which is associated with the cells position in the multicellular structure. Subsequently, the multicellular structure can be dissociated into single cells and a single cell transcriptome analysis performed, as well as other types of single cell analyses. By preserving positional information in the analyzed single cells, biological processes within the tissue can be mapped. By these methods, the effects of the local environment surrounding a cell on its state and various functions can be elucidated, and intra-tissue processes can be mapped and observed. Likewise, coordinated actions by multiple cells within a tissue can be mapped and tracked over time.
A method of identifying a target microbe in a specimen and including the steps of a) obtaining a specimen, b) lysing the specimen to release a plurality of rRNA molecules from one or more first target microbes in the specimen; c) contacting the specimen with a plurality of first oligonucleotide probe sets configured to selectively bind to rRNA molecules released from the target microbe thereby forming a plurality of first hybridized complexes, each first hybridized complex including one first capture probe and one first detector probe and one of the plurality of rRNA molecules, and d) analyzing the first hybridized complexes to identify a first target microbe in the specimen.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
Filtration membrane with improved mechanical stability and increased resistance to pressure is provided. The filtration membrane is useful for in vivo implantable filtration devices, such as, an artificial kidney. In vivo implantable filtration devices are also provided.
The disclosure features methods directed to modifying regulatory T (Treg) cell stability by inhibiting the expression of one or more transcription factors and/or inhibiting one or more genes or gene products regulated by the transcription factors. The disclosure also features compositions comprising the Treg cells having modified stability.
Compositions, methods of making, and using modified immune cells such as NK cells to treat cancer, viral and microbial infection. The modified CISH -/- NK cells exhibit hypersensitivity to cytokines such as IL-2 and/or IL-15 and maintain expansion and anti-tumor functions.
Methods, compositions and kits for detection of a taxon of pathogenic microorganisms in a sample are provided. Also provided are methods, compositions and kits for detecting taxons of pathogenic microorganisms present in low titers in a sample. Compositions, methods and kits for detection of pathogenic co-infections are also provided.
C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
Provided herein are inhibitors of SLC26A3, which is an anion (CV, HCO3, oxalate) exchanger expressed in intestinal epithelial cells. SLC26A3 inhibitors have potential utility for treatment of constipation including chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), constipation-predominant irritable bowel syndrome (IBS-C), cystic fibrosis-associated constipation, meconium ileus, distal intestinal obstruction syndrome, calcium oxalate kidney stone disease, enteric hyperoxaluria and primary hyperoxalurias.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 9/52 - Sustained or differential release type
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
21.
METHODS AND COMPOSITIONS FOR HAIR GROWTH BY ACTIVATING AUTOPHAGY
Disclosed are methods improving or stimulating hair regeneration; treating, inhibiting, or reducing hair loss; improving or stimulating hair growth; treating, inhibiting, or reducing pigmentation loss; and/or improving or stimulating pigmentation production in a subject with one or more autophagy inducing agents.
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
A61Q 7/00 - Preparations for affecting hair growth
Disclosed herein are methods of treating cancer in a subject, comprising: administering at least one PAK4 inhibitor to the subject; and in certain embodiments administering at least one immunostimulatory agent to the subject. In some aspects, the immunostimulatory agent can be a checkpoint inhibitor. In certain aspects the checkpoint inhibitor can be an anti-PDl antibody.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
A61P 35/04 - Antineoplastic agents specific for metastasis
Described herein are compositions, systems, methods, and kits utilizing RNA binding protein fusions, such as CRISPR-Cas protein fusions comprising a guide nucleotide sequence-programmable RNA binding protein, and a translation modifier protein. Also, described herein are compositions, systems, methods, and kits utilizing CRISPR-Cas associated RNA fusions comprising a guide nucleotide sequence-programmable RNA and an internal ribosome entry site (IRES). The compositions, systems, methods, and kits described herein are useful to upregulate or downregulate mRNA translation.
Provided herein is a method of reprogramming a non-neuronal cell to a neuron. Aspects of the present disclosure relate to using cell reprogramming agent suppresses the expression or activity of PTB to convert a non-neuronal cell into a neuron. Also provided herein is a method of treating neurodegenerative disease by reprogramming non-neuronal cells in vivo to functional neurons.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
26.
COGNITION AND MEMORY ENHANCEMENT VIA MULTIPLE ODORANT STIMULATION
Disclosed herein are methods, kits, and devices for improving cognitive function and memory through olfactory stimulation. In some embodiments, olfactory stimulation is performed by releasing one or more scents according to an olfactory stimulation regimen or schedule. The methods, kits and devices described herein can provide a large impact on cognition with minimal effort and cost. They can be used widely and effectively among older adults, children, and other populations in need of improved cognitive performance.
A61M 21/00 - Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
The disclosure provides methods and compositions for determining the kinase activity profile of a biological sample, e.g., that contains multiple kinases.
A senes of alloys of Co, Ni, Al, W, Ta, and Cr, wherein the alloy comprises a solid solution of gamma and gamma prime alloy phases, the Ni content is greater than 25% at.%, the Al content is greater than 10 at, %, the Cr content is greater than 2 at.%, and the Nr Co ratio is between 0.5 and 1.5. In one or more examples, the alloy further comprises one or more of C, B, and a reactive element metal. Embodiments of the alloy simultaneously possess a high solvus temperature, a high fraction of the strengthening ?'-L12 phase, good oxidation resistance and highly favorable solidification characteristics.
Methods are provided for treating a subject for glioblastoma, including e.g., an EGFRvIII negative glioblastoma. The methods of the present disclosure involve administering to a subject a molecular circuit that includes a binding triggered transcriptional switch (BTTS) that binds to a priming antigen expressed by the subjects glioblastoma multiforme (GBM) that, when bound to the priming antigen, induces one or more encoded therapeutics specific for one or more antigens expressed by the GBM. Nucleic acids containing sequences encoding all or portions of such circuits are also provided, as well as cells, expression cassettes and vectors that contain such nucleic acids. Also provided are kits for practicing the described methods.
Provided are methods of treating a subject for a heterogeneous cancer. The methods of the present disclosure include integrating at least two antigens expressed heterogeneously in the cancer and/or in the cancer microenvironment, including where the antigens are expressed in trans, i.e., expressed by at least two different cell types. The subject methods will generally involve immune cells into which circuits have been introduced that employ one or more binding triggered transcriptional switches and one or more encoded therapeutics specific for antigens expressed by cancer cells and/or by neighboring non-cancer cells. Nucleic acids containing sequences encoding all or portions of such circuits are also provided, as well as cells, expression cassettes and vectors that contain such nucleic acids. Also provided are kits for practicing the described methods.
Methods are provided for treating a subject for an EGFRvIII expressing glioblastoma. The methods of the present disclosure involve administering to the subject a molecular circuit that is primed by EGFRvIII to induce one or more encoded therapeutics specific for one or more antigens expressed by the glioblastoma. Nucleic acids containing sequences encoding all or portions of such circuits are also provided, as well as cells, expression cassettes and vectors that contain such nucleic acids. Also provided are kits for practicing the described methods.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention is a composition comprising an aqueous dispersion of metal oxide pigment particles coated with a polymer comprising structural units of an alkyltrihydroxysilane or a salt thereof and a dialkyldihydroxysilane or a salt thereof. The composition of the present invention provides hydrophobicity to pigment particles, thereby imparting water resistance, and allows for high loadings of pigment in water without increased viscosity.
rovided herein are compounds that inhibit protein secretion, e.g., via inhibition of Sec61. Also provided are compositions of the inhibitor compounds, and methods of using these inhibitors. The compounds disclosed herein can be used, e.g., for the treatment of cancer, arthritis, and/or inflammation.
Provided herein are, inter alia, biosensors and electrochemical cells comprising electronically conductive polymers and viral particles; diagnostic kits; and methods of detecting compounds in samples.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
G01N 27/22 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating capacitance
The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.
A deep learning-based digital staining method and system are disclosed that enables the creation of digitally/virtually-stained microscopic images from label or stain-free samples based on autofluorescence images acquired using a fluorescent microscope. The system and method have particular applicability for the creation of digitally/virtually-stained whole slide images (WSIs) of unlabeled/unstained tissue samples that are analyzes by a histopathologist. The methods bypass the standard histochemical staining process, saving time and cost. This method is based on deep learning, and uses, in one embodiment, a convolutional neural network trained using a generative adversarial network model to transform fluorescence images of an unlabeled sample into an image that is equivalent to the brightfield image of the chemically stained-version of the same sample. This label-free digital staining method eliminates cumbersome and costly histochemical staining procedures and significantly simplifies tissue preparation in pathology and histology fields.
C07C 275/24 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A61K 31/401 - Proline; Derivatives thereof, e.g. captopril
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
C12N 9/00 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
C12N 15/52 - Genes encoding for enzymes or proenzymes
There are provided, inter alia, compositions and methods for treatment of chemoresistant cancer (breast cancer). The methods include administering to a subject in need a therapeutically effective amount of a chemotherapeutic agent and a ROR- 1 antagonist. Further provided are pharmaceutical compositions including chemotherapeutic agent, ROR- 1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the chemotherapeutic agent is paclitaxel and the ROR- 1 antagonist is cirmtuzumab.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/04 - Antineoplastic agents specific for metastasis
40.
A MODULAR SYSTEM FOR GENE AND PROTEIN DELIVERY BASED ON AAV
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Byrne, Leah
Ozturk, Bilge Esin
Day, Timothy
Abstract
In one embodiment, the invention provides an Adeno-Associated Virus (AAV) comprising an exterior surface, which surface comprises one or more peptide tags that form a bond with a binding-partner, wherein the AAV is a live virus. In another embodiment, the invention provides a conjugate comprising at least one such AAV and at least one polypeptide comprising a first domain which is the binding-partner for the tag and a second domain, which is a bioactive polypeptide. In another embodiment, the invention provides a conjugate comprising at least one such AAV (first AAV) and at least one second AAV, which second AAV comprises a second exterior surface, which second exterior surface comprises at least one binding-partner for the tag or for a third linker molecule, wherein the at least one first AAV and the at least one second AAV are bound.
Chimeric antigen receptor (CAR)-expressing Tregs specifically target an antigen present in the joint of RA patients to induce a localized and effective immunosuppressive response.
Provided herein are energy storage devices comprising a first electrode comprising a layered double hydroxide, a conductive scaffold, and a first current collector; a second electrode comprising a hydroxide and a second current collector; a separator; and an electrolyte. In some embodiments, the specific combination of device chemistry, active materials, and electrolytes described herein form storage devices that operate at high voltage and exhibit the capacity of a battery and the power performance of supercapacitors in one device.
H01G 11/28 - Electrodes characterised by their structure, e.g. multi-layered, porosity or surface features arranged or disposed on a current collector; Layers or phases between electrodes and current collectors, e.g. adhesives
H01G 11/50 - Electrodes characterised by their material specially adapted for lithium-ion capacitors, e.g. for lithium-doping or for intercalation
H01G 11/86 - Processes for the manufacture of hybrid or EDL capacitors, or components thereof specially adapted for electrodes
H01M 4/52 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
43.
THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS
The disclosure provides for methods and treatments of TLR2- mediated diseases and disorders comprising administering an antibody, antibody fragment, or polypeptide that binds to and inhibits the biological activity of oxidized phospholipids.
The disclosed embodiments relate to a system that performs microscopy imaging with an extended depth of field. This system includes a stage for holding a sample, and a light source for illuminating the sample, wherein the light source produces ultraviolet light with a wavelength in the 230 nm to 300 nm range to facilitate microscopy with ultraviolet surface excitation (MUSE) imaging. The system also includes an imaging device, comprising an objective that magnifies the illuminated sample, and a sensor array that captures a single image of the magnified sample. The system also includes a controller, which controls the imaging device and/or the stage to scan a range of focal planes for the sample during an acquisition time for the single image. The system additionally includes an image-processing system, which processes the single image using a deconvolution technique to produce a final image with an extended depth of field.
G01N 21/00 - Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
G02B 7/04 - Mountings, adjusting means, or light-tight connections, for optical elements for lenses with mechanism for focusing or varying magnification
45.
METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISORDRES USING ANTI-VEGF AGENTS
Provided are methods and compositions for treatment of angiogenic disorders using anti-VEGF agents. The anti-VEGF agents comprise VEGF binding domains and have the ability to bind vitreous. Provided are exemplary embodiments of Fc-IgG fusion proteins with VEGF binding domains with strong heparin-binding characteristics, strong inhibition of VEGF mitogenic activity, and improved pharmacokinetics, namely longer half-lives of the anti-VEGF agents and consequently less frequent dosing.
In various embodiments novel biodegradable acid-activated acid releasing nanoparticles (acNPs) are provided that are used as a targeted strategy to manipulate lysosomal acidity and autophagy. These acNPs based, in certain embodiments, on fluorinated polyesters are degraded at pH 6.0 (pH reported in dysfunctional lysosomes), and release component acids that further lower the lysosomal pH, and thereby increasing autophagic flux and cellular function of hepatocytes under LT. The acNPs can serve as a therapeutic in restoring liver-diseases.
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Abate, Adam R.
Hatori, Makiko N.
Liu, Leqian
Kim, Samuel
Modavi, Cyrus
Abstract
The methods described herein, referred to as particle-templated emulsification (PTE), provide an improved approach for generating a monodisperse emulsion that encapsulates target particles of interest without requiring the use of a microfluidic device. Monodisperse droplets may be effectively obtained by using monodisperse particles to template the formation of droplets, which can include, e.g., monodisperse single-emulsion droplets, multiple-emulsion droplets, or Giant Unilamellar Vesicles (GUV), without destroying the integrity of the droplets.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula (I).
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
C07D 405/00 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
C07D 405/02 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
49.
HUMAN ANTIBODIES THAT BIND AND ARE INTERNALIZED BY MESOTHELIOMA AND OTHER CANCER CELLS
In certain embodiments internalizing anti-CD146 antibodies and conjugates thereof are provided. It was discovered that anti-CD146 antibodies are capable of targeting both epithelioid and sarcamatous subtypes of mesothelioma cells. In certain embodiments methods of detecting and/or treating mesothelioma are provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
50.
RECOMBINANT IGG FC MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Spirig, Rolf
Baz Morelli, Adriana
Verkman, Alan
Tradtrantip, Lukmanee
Abstract
This disclosure provides the use of recombinant IgG Fc multimers for the treatment of neuromyelitis optica (NMO), and methods of treating NMO by administering such multimers.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention is a composition comprising an aqueous dispersion of metal oxide pigment particles coated with a polymer comprising structural units of an alkyltrihydroxysilane or a salt thereof. The composition of the present invention provides hydrophobicity to pigment particles, thereby imparting water resistance, and allows for high loadings of pigment in water without increased viscosity.
The present disclosure relates to measuring gene expression of cells of a blood sample obtained from a mammalian subject suspected of having a tick-borne disease. In particular, the present disclosure provides tools for determining whether a human subject has acute Lyme disease by transcriptome profiling a peripheral blood mononuclear cell sample from the subject.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
G16B 25/00 - ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
53.
METHODS FOR CONDUCTIVE ADHESIVES BASED ON GRAPHENE AND APPLICATIONS THEREOF
The present disclosure relates to conductive adhesives and inks. The disclosed conductive adhesives include glues and epoxies, based on graphene and graphene/carbon composites and the methods of manufacture thereof, such conductive adhesives exhibiting excellent conductivity, thermal properties, durability, low curing temperatures, mechanical flexibility, and reduced environmental impact. Further, adhesives with conductive additives such as silver nanowires and the methods of production thereof are disclosed herein.
C09J 4/06 - Adhesives based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond in combination with a macromolecular compound other than an unsaturated polymer of groups
C09J 133/06 - Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, the oxygen atom being present only as part of the carboxyl radical
54.
BIOFOULING RESISTANT COATINGS AND METHODS OF MAKING AND USING THE SAME
Disclosed herein are compositions to use in biofouling-resistant coatings, biofouling-resistant coatings, methods of making biofouling-resistant coatings, biofouling-resistant devices, and methods of making biofouling-resistant devices.
The invention relates to compounds that promote hematopoietic regeneration. The invention further relates to methods of promoting hematopoietic regeneration using the novel compounds of the invention.
C07C 225/22 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07C 233/11 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
C07C 233/36 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07D 207/333 - Radicals substituted by oxygen or sulfur atoms
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
56.
ANTI-CXCR5 ANTIBODIES AND COMPOSITIONS AND USES THEREOF
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Methods of the disclosed precision guided sterile insect technique (pgSIT) include methods for directing male sexing in a genetically modified insect and methods of producing a progeny of genetically modified sterile male insect egg. These methods include integrating at least one nucleic acid sequence into a genome of a first insect, the at least one nucleic acid sequence having at least one first guide polynucleotide targeting a female-essential genomic sequence that is required for female-specific viability, introducing an endonuclease into a second insect, and genetically crossing the first insect and the second insect thereby producing progeny expressing the endonuclease and the at least one nucleic acid sequence. For male sterility a second guide polynucleotide targets a male sterility genomic sequence that is required for male-specific sterility.
Provided are compositions and methods for detecting a target DNA (double stranded or single stranded) in a sample. In some embodiments, a subject method includes: (a) contacting the sample with: (i) a type V CRISPR/Cas effector protein (e.g., a Cas12 protein such as Cas12a, Cas12b, Cas12c, Cas12d, Cas12e); (ii) a guide RNA (comprising a region that binds to the type V CRISPR/Cas effector protein, and a guide sequence that hybridizes with the target DNA); and (iii) a detector DNA that is single stranded (i.e., a "single stranded detector DNA") and does not hybridize with the guide sequence of the guide RNA; and (b) measuring a detectable signal produced by cleavage (by the type V CRISPR/Cas effector protein) of the single stranded detector DNA. Also provided are compositions and methods for cleaving single stranded DNAs (e.g., non-target ssDNAs), e.g., inside of a cell.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Choe, Joseph H.
Langridge, Paul
Lim, Wendell A.
Roybal, Kole T.
Struhl, Gary
Abstract
Provided are chimeric polypeptides which modulate various cellular processes following cleavage of a force sensor cleavage domain, including non-Notch force sensor cleavage domains, induced upon binding of a specific binding member of the chimeric polypeptide with its binding partner. Methods of using force sensor cleavage domain-containing chimeric polypeptides to modulate cellular functions, including e.g., modulation (including induction or repression) of gene expression, are also provided. Nucleic acids encoding the subject chimeric polypeptides and associated expression cassettes and vectors as well as cells that contain such nucleic acids and/or expression cassettes and vectors are provided. Also provided, are methods of monitoring cell-cell signaling and method of treating a subject using the described components, as well as kits for practicing the subject methods.
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The reaction rate of hydrocarbon pyrolysis can be increased to produce solid carbon and hydrogen by the use of molten materials which have catalytic functionality to increase the rate of reaction and physical properties that facilitate the formation and contamination-free separation of the solid carbon. Processes, materials, reactor configurations, and conditions are disclosed whereby methane and other hydrocarbons can be decomposed at high reaction rates into hydrogen gas and carbon products without any carbon oxides in a single reaction step. The process also makes use of specific properties of selected materials with unique solubilities and/ or wettability of products into (and/or by) the molten phase to facilitate generation of purified products and increased conversion in more general reactions.
B01J 8/04 - Chemical or physical processes in general, conducted in the presence of fluids and solid particles; Apparatus for such processes with stationary particles, e.g. in fixed beds the fluid passing successively through two or more beds
61.
TREATMENT OF OPIOID USE DISORDER, OPIOID WITHDRAWAL SYMPTOMS AND CHRONIC PAIN
The current methods and compositions provide for a novel and effective therapeutic method for treating opioid use disorder, opioid withdrawal symptoms and/or chronic pain. Accordingly, certain aspects of the disclosure relate to a method for treating opioid use disorder, opioid withdrawal symptoms and/or chronic pain in a subject, the method comprising administering at least one purified cannabinoid compound and a partial opioid agonist. In some embodiments, the method comprises administering a composition comprising cannabidiol and buprenorphine.
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
62.
COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION
The present disclosure provides a method of restoring or enhancing visual function in an individual, the method comprising administering to the individual a nucleic acid comprising a nucleotide sequence encoding one or more of a medium wavelength cone opsin (MW-opsin), a long wavelength cone opsin (LW-opsin), and a short wavelength cone opsin (SW-opsin). One or more of the MW-opsin, LW-opsin, and SW-opsin is expressed in a retinal cell in the individual, thereby restoring or enhancing visual function.
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
The present disclosure relates generally to detection of non-coding RNAS molecules in a sample or diagnosis of subject based upon detection or quantification of non-coding nucleic acid sequences in a sample, specifically to identify and use of molecular biomarkers for cancer including breast cancer.
Provided are compositions and methods that include one or more of: (1) a "CasZ" protein (also referred to as a CasZ polypeptide), a nucleic acid encoding the CasZ protein, and/or a modified host cell comprising the CasZ protein (and/or a nucleic acid encoding the same); (2) a CasZ guide RNA that binds to and provides sequence specificity to the CasZ protein, a nucleic acid encoding the CasZ guide RNA, and/or a modified host cell comprising the CasZ guide RNA (and/or a nucleic acid encoding the same); and (3) a CasZ transactivating noncoding RNA (trancRNA) (referred to herein as a "CasZ trancRNA"), a nucleic acid encoding the CasZ trancRNA, and/or a modified host cell comprising the CasZ trancRNA (and/or a nucleic acid encoding the same).
Polyamines with lengths carefully tailored to the framework dimensions are appended to metal -organic frameworks such as Mg2(dobpdc) (dobpdc4- = 4,4'- dioxidobiphenyl-3,3'- dicarboxylate) with the desired loading of one polyamine per two metal sites. The polyamine-appended materials show step-shaped adsorption and desorption profiles due to a cooperative CO2 adsorption/desorption mechanism. Several disclosed polyamine-appended materials exhibit strong ability to capture CO2 from various compositions. Increased stability of amines in the framework has been achieved using high molecular weight polyamine molecules that coordinate multiple metal sites in the framework. The preparation of these adsorbents as well as their characterization are provided.
B01D 53/04 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
B01J 20/30 - Processes for preparing, regenerating or reactivating
Disclosed herein, inter alia, are methods of use and composition of novel inhibitors that target the Smac binding site of a variety of inhibitor of apoptosis proteins that contain a Bir domain, including XIAP, cIAP1, cIAP2, or other IAP proteins.
Typical electrochemical sensors measure target-induced changes in current output. Such measures of target binding are inconsistent across individual sensors, and furthermore, signal will drift over time when the sensor is deployed for long periods. These shortcomings can be avoided by the novel use of chronoamperometry to measure current decay kinetics as the indicator of target binding. Current decay lifetimes will vary in a concentration dependent manner, but remain stable across individual sensors and over time, allowing for calibration-free operation. By these methods, aptamer based electrochemical sensors and other sensor types may be deployed in vivo for extended periods of time and will provide accurate measurement of target binding without calibration.
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
A61B 5/1495 - Calibrating or testing in vivo probes
69.
TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORS
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Roth, Theodore Lee
Shifrut, Eric
Marson, Alexander
Saus, Cristina Puig
Ribas, Antoni
Abstract
Provided herein are methods and compositions for editing the genome of a human T cell. In some embodiments, a heterologous T cell receptor (TCR)-ß chain and a heterologous TCR-a chain are inserted into exon 1 of a TCR subunit constant gene in the genome of the T cell.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Jin, Hailing
Abstract
The present invention relates to pathogen-resistant plants. In one aspect, plants comprising a heterologous expression cassette are provided, wherein the expression cassette comprises a polynucleotide that inhibits expression of a fungal pathogen gene and wherein the plant has increased resistance to a fungal pathogen or multiple pathogens compared to a control plant lacking the expression cassette. In another aspect, contacting a plant or a plant part with double stranded RNAs or small RNAs that inhibit expression of a fungal target gene or genes from multiple pathogens, wherein the plant has increased resistance to a pathogen or multiple pathogens compared to control plants that has not been contacted with the RNAs. Methods of making and cultivating pathogen-resistant plants are also provided.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
X-ray crystallography has defined conformational properties of a key functional region of the G protein of respiratory syncytial virus (RSV). Mimics of these epitopes have utility as immunogens, as tools for discovery of antibodies and other monoclonal binding agents, and as pharmacological agents to modulate activity of the host receptors for this viral protein.
Disclosed herein are systems, methods, devices, and media for carrying out medical diagnosis of ophthalmic diseases and conditions. Deep learning algorithms enable the automated analysis of ophthalmic images to generate predictions of comparable accuracy to clinical experts.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Miranda, Matilde
Flores, Aimee
Lowry, William E.
Christofk, Heather R.
Abstract
The present disclosure relates to pharmaceutical compositions containing electron transport chain (ETC) inhibitors, which are capable of promoting hair growth. The disclosure further relates to methods of promoting hair growth or treating conditions or disorders affecting hair growth, such as baldness or alopecia.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present dislcsoure also provides methods oadministering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Sheikh, Farah
Zhang, Jing
Abstract
Disclosed herein are methods of treating arrhythmogenic right ventricular cardiomyopathy in a subject, comprising administering a gene therapy construct comprising a connexin 43 sequence, wherein as a result of the administration, connexin 43 levels in at least a portion of the heart are increased. Further disclosed are other cardiovascular diseases can be treated with the method.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 9/00 - Drugs for disorders of the cardiovascular system
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Isacoff, Ehud Y.
Trauner, Dirk
Broichhagen, Johannes
Levitz, Joshua
Abstract
The present disclosure provides a conjugate comprising: a) an affinity agent that specifically binds a target ligand-binding polypeptide; and b) a photoisomerizable regulator comprising: i) a photoisomerizable moiety; and ii) a ligand that binds to the target ligand-binding polypeptide. The present disclosure provides cells comprising a conjugate of the present disclosure. The present disclosure provides methods of using a conjugate of the present disclosure to modulate activity of a target polypeptide, and to modulate activity of a target cell or cell population.
C07K 14/36 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptomyces (G)
C07C 245/08 - Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
C07K 14/195 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
78.
CLAUDIN6 ANTIBODIES AND METHODS OF TREATING CANCER
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Conklin, Dylan
Slamon, Dennis
O'Brien, Neil
Palazzolo, Mike
Von Euw, Erika
Abstract
The present disclosure provides antigen-binding proteins which bind to Claudin- 6 (CLDN6). In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Marsala, Martin
Miyanohara, Atsushi
Tadokoro, Takahiro
Abstract
The present invention provides a therapy for treating neuropathic pain by subpial administration of small quantities of a composition for spinal segment-specific upregulation of GAD65 (glutamatedecarboxylase) gene and VGAT (vesicular GABA transporter) gene, which is effective for induction of nociceptive effects by potentiating release of vesicular GABA from infected dorsal horn neurons into the synaptic cleft.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Corn, Jacob
Dewitt, Mark
Shams, Arik
Foss, Dana V.
Abstract
In certain embodiments a construct for performing gene editing in a mammalian cell is provided. In certain embodiments the construct comprises a targeting moiety that binds a surface marker on a cell (e.g., surface receptor), where the targeting moiety is attached to a complex comprising a class 2 CRISPR/Cas endonuclease complexed with a corresponding CRISPR/Cas guide RNA that hybridizes to a target sequence within the genomic DNA of the cell.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Perebikovsky, Alexandra
Churchill, Bernard
Churchman, Scott
Haake, David Arnold
Halford, Colin Wynn
Liu, Yujia
Madou, Marc
Monti, Gabriel
Abstract
There is described a system for growing a microorganism in liquid culture, the system comprising: a driving apparatus configured to house and oscillate a microfluidic cartridge; and a microfluidic cartridge comprising at least one incubation chamber, such that when the system is in use, the incubation chamber may be oscillated back and forth along an oscillation path using a preferred oscillation protocol. There is also described a method of growing a microorganism in liquid culture, the method comprising disposing a microorganism and suitable growth medium into an incubation chamber; and mixing the microorganism and growth medium by oscillating the incubation chamber back and forth along an oscillation path using a preferred oscillation protocol. There is also described a microfluidic cartridge that may be used to grow microorganisms using the system and methods described above.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
C12M 1/10 - Apparatus for enzymology or microbiology rotatably mounted
C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
82.
ROBOTIC SYSTEMS AND METHODS FOR ROBUSTLY GRASPING AND TARGETING OBJECTS
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Goldberg, Kenneth Yigael
Mahler, Jeffrey Brian
Matl, Matthew
Abstract
Embodiments are generally directed to generating a training dataset of labelled examples of sensor images and grasp configurations using a set of three-dimensional (3D) models of objects, one or more analytic mechanical representations of either or both of grasp forces and grasp torques, and statistical sampling to model uncertainty in either or both sensing and control. Embodiments can also include using the training dataset to train a function approximator that takes as input a sensor image and returns data that is used to select grasp configurations for a robot grasping or targeting mechanism.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Keenan, Richard M.
Backes, Bradley J.
Maly, Dustin J.
Reynolds, Charles
Whittaker, Ben
Knight, Jamie
Sutton, Jon
Hynd, George
Papa, Feroz R.
Oakes, Scott A.
Abstract
The present invention provides novel compounds, compositions and methods for treating or preventing an IRE1a-related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Schaffer, David V.
Ojala, David Stephen
Romero, Philip A.
Abstract
The present disclosure provides recombinant adeno-associated virus virions with variant capsid protein, where the recombinant AAV (rAAV) virions exhibit one or more of increased ability to cross neuronal cell barriers, increased infectivity of a neural stem cell, increased infectivity of a neuronal cell, and reduced susceptibility to antibody neutralization, compared to a control AAV, and where the rAAV virions comprise a heterologous nucleic acid. The present disclosure provides methods of delivering a gene product to a neural stem cell or a neuronal cell in an individual. The present disclosure also provides methods of modifying a target nucleic acid present in a neural stem cell or neuronal cell.
C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
85.
MOLECULAR BACTERIOTHERAPY TO CONTROL SKIN ENZYMATIC ACTIVITY
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Gallo, Richard L.
Williams, Michael
Abstract
The invention provides a purified polypeptide which inhibits (i) protease production and/or activity of keratinocytes, (ii) inhibits IL-6 production and/or activity of keratinocytes, (iii) inhibits production of phenol soluble modulin alpha 3 from Staphylococcus aureus and/or (iv) inhibits agr production and/or activity by S. aureus. Further provided is a topical formulation comprising the polypeptide. Provided is a recombinant microorganism comprising a vector or polynucleotide encoding the polypeptide. Further provided is a probiotic composition comprising the recombinant microorganism. The invention also provides kits and articles of manufacture comprising the polypeptide and/or the recombinant microorganism.
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 14/31 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Verkman, Alan
Levin, Marc H.
Abstract
The disclosure provides, inter alia, topical pharmaceutical compositions comprising active agents, methods for increasing tear production using the topical pharmaceutical compositions, and methods for treating dry eye disorders using the topical pharmaceutical compositions.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Bachman, Mark
Babikian, Sarkis
Li, Guann-Pyng
Abstract
A miniature wireless pressure sensor has an inductor and a capacitor. The inductor and the capacitor form a L-C resonator with a resonate frequency. The inductor's inductance is affected by a slidable electro-magnetic element. When an outside pressure is applied onto the element, it causes the element to move and such movement changes the inductance of the inductor. Because of that, the resonate frequency is changed. Therefore, the change in resonate frequency indicates a change in the outside pressure. The L-C resonator is calibrated to correlate with the outside pressure. Such a miniature wireless pressure sensor facilitates the monitoring of physiological pressure in different part of human body such as eyes and cranium.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Churchill, Bernard
Churchman, Scott Adam
Haake, David Arnold
Halford, Colin Wynn
Knauf, Roger
Monti, Gabriel
Kido, Horacio
Madou, Marc
Perebikovsky, Alexandra
Liu, Yujia
Gussin, Daniel
Abstract
A method for determining the susceptibility of bacteria in a clinical sample comprising urine or an inoculant derived therefrom to an antibiotic agent may include the steps of a) inoculating a test portion of the clinical sample in a medium containing a predetermined concentration of the antibiotic agent; b) inoculating a control portion of the clinical sample in a medium that does not contain the antibiotic agent; c) incubating the test portion for an incubation period; d) incubating the control portion for the incubation period; e) determining a quantity of RNA in the test portion and a quantity of RNA in the control portion at the conclusion of the incubation period that is less than 480 minutes after the completion of step a); and f) determining a susceptibility of the bacteria to the antibiotic agent by comparing the quantity of RNA in the test portion to the quantity of the RNA in the control portion.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
YARA INTERNATIONAL ASA (Canada)
BASF CORPORATION (Canada)
Inventor
Sant, Gaurav N.
Falzone, Gabriel D.
Oey, Tandre
Franke, Wolfram
Seiler, Paul
La Plante, Erika Callagon
Abstract
A manufacturing method includes: (1) incorporating at least one soluble, calcium, magnesium, or other divalent cation-containing additive into a concrete mixture including aggregates prone to alkali-silica reaction; and (2) curing the concrete mixture to form a concrete product.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Wang, Huawei
Klemke, Richard
Abstract
Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
METKINE THERAPEUTICS, INC. (Canada)
Inventor
Jablons, David M.
Xu, Wei
You, Liang
Liu, Shu
Yuan, Shendong
Ma, Sunghoon
Mac, Morrison
Abstract
This invention provides, among other things, compounds useful for treating diseases such as fibrosis and/or cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
93.
METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF
C07D 263/34 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
A61K 31/424 - Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Monti, Gabriel
Halford, Colin Wynn
Perebikovsky, Alexandra
Liu, Yujia
Kido, Horacio
Haake, David Arnold
Madou, Marc
Gussin, Daniel
Churchill, Bernard
Abstract
There is described a method for extracting a target chemical compound from a cellular material in a sample. The method comprising the steps of: subjecting the sample to mechanical lysis to cause disruption of a cellular membrane in the cellular material; contacting the sample with an alkaline material to produce a lysate composition comprising the target chemical compound; and recovering the lysate composition from the sample. There is also described a method for producing a lysate composition comprising RNA from a mammalian bodily fluid sample comprising a cellular material. There is also described a method for extracting a nucleic acid from a cellular material in a bodily fluid or an inoculant derived therefrom.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Nguyen, Quyen T.
Whitney, Michael A.
Hingorani, Dina
Tsien, Roger Y.
Adams, Stephen
Abstract
The present invention provides methods for guiding preservation of human neurons or human nerves during surgery by administering a fluorescently-labeled peptide that specifically binds to the human neurons or human nerves. The invention further provides human neuron or nerve targeting molecules comprising fluorescently- labeled peptides that specifically bind to human neurons or human nerves and compositions thereof.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61P 25/00 - Drugs for disorders of the nervous system
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 17/02 - Peptides being immobilised on, or in, an organic carrier
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (Canada)
Inventor
Long, Jeffrey R.
Weston, Simon Christopher
Milner, Phillip J.
Siegelman, Rebecca L.
Abstract
Achieving the selective and reversible adsorption of CO2 from humid, low partial pressures streams such as the flue gas resulting from the combustion of natural gas in combined cycle power plants (4% CO2) is challenging due to the need for high thermal, oxidative, and hydrolytic stability as well as moderate regeneration conditions to reduce the energy of adsorption/desorption cycling. Appending cyclic primary, secondary diamines, exemplified by 2-(aminomethyl)piperidine (2-ampd), to the metalorganic frameworks Mg2(dobpdc) (dobpdc4 = 4,4-dioxidobiphenyl-3,3-dicarboxylate), Mg2(dotpdc) (dotpdc4 = 4,4''-dioxido-[1,1':4',1''-terphenyl]-3,3''-dicarboxylate) or Mg2(pc-dobpdc) (pc-dobpdc4 = dioxidobiphenyl-4,4'-dicarboxylate) produces adsorbents of the classes EMM-44, EMM-45, and EMM-46, respectively, that display step-shaped adsorption of CO2 at the partial pressures required for 90% capture from natural gas flue gas at temperatures up to or exceeding 60 °C. Using a cyclic diamine in place of a diamine functionalized with bulky alkyl groups enables fast adsorption/desorption kinetics with sharp CO2 adsorption and desorption steps.
B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
B01D 53/04 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
97.
OVERCOMING TWO CARBON DIOXIDE ADSORPTION STEPS IN DIAMINE-APPENDED METAL-ORGANIC FRAMEWORKS
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (Canada)
Inventor
Long, Jeffrey R.
Weston, Simon Christopher
Milner, Phillip J.
Martell, Jeffrey D.
Siegelman, Rebecca L.
Abstract
Primary, secondary (10,20) alkylethylenediamine- and alkylpropylenediamine- appended variants of metal-organic framework are provided for CO2 capture applications. Increasing the size of the alkyl group on the secondary amine enhances the stability to diamine volatilization from the metal sites. Two-step adsorption/desorption profiles are overcome by minimizing steric interactions between adjacent ammonium carbamate chains. For instance, the isoreticularly expanded framework Mg2(dotpdc) (dotpdc4- =4,4"dioxido - [1, 1':4',1"-terphenyl]-3,3"-dicarboxylate), yields diamine-appended adsorbents displaying a single CO2 adsorption step. Further, use of the isomeric framework Mg-IRMOF-74-II or Mg2(pc-dobpdc) (pc-dobpdc4- = 3,3-dioxidobiphenyl-4,4-dicarboxylate, pc = para-carboxylate) also leads to a single CO2 adsorption step with bulky diamines. By relieving steric interactions between adjacent ammonium carbamate chains, these frameworks enable step-shaped CO2 adsorption, decreased water co-adsorption, and increased stability to diamine loss. Variants of Mg2(dotpdc) and Mg2(pc-dobpdc) functionalized with large diamines such as N-(n-heptyl)ethylenediami ne have utility as adsorbents for carbon capture applications.
B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
98.
S-ENANTIOMERS OF BETA-HYDROXYBUTYRATE AND BUTANEDIOL AND METHODS FOR USING SAME
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
THE J. DAVID GLADSTONE INSTITUTES (Canada)
Inventor
Verdin, Eric
Newman, John C.
Abstract
In various embodiments a compound comprising the enantiomerically enriched S-isomer S-BHB-S-1,3-butanediol is provided along with methods of use thereof.
C07C 69/675 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Kells, Adrian Philip
Schreck, Stefan
Luttich, Edward H.
Bloch, Kenneth A.
Bankiewicz, Krystof
Abstract
The present disclosure presents a trajectory array guide system (19) for defining a trajectory to a target location in the brain of a subject and for guiding an elongated tool along the trajectory. The trajectory array guide system (19) can comprise a base (450), an array guide (320), an imaging unit (360), and an elongated handle (440) configured for connection with a stereotaxic navigation system. The present disclosure presents a method of using a trajectory array guide system (19) for defining a trajectory to a target location in the brain of a subject and for guiding an elongated tool along the trajectory.
A61B 90/10 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis
A61B 90/11 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
100.
SIMPLE ROUTE TO HIGHLY CONDUCTIVE POROUS GRAPHENE FROM CARBON NANODOTS FOR SUPERCAPACITOR APPLICATIONS
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
Strauss, Volker
Kaner, Richard B.
El-Kady, Maher F.
Abstract
Disclosed herein are methods and compositions directed to a promising class of nanomaterials called organic nanoparticles, or carbon nanodots. The present disclosure provides a facile method for the conversion of biomolecule-based carbon nanodots into high surface area three-dimensional graphene networks with excellent electrochemical properties.
H01M 8/22 - Fuel cells in which the fuel is based on materials comprising carbon or oxygen or hydrogen and other elements; Fuel cells in which the fuel is based on materials comprising only elements other than carbon, oxygen or hydrogen
patents
